Acetazolamide

Analytical Profiles of Drug Substances and Excipients

Volumn 22, Issue C, 1993, Pages 1-32

  Parasrampuria, Jagdish ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042424475     PISSN: 10756280     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0099-5428(08)60238-5     Document Type: Article

References (62)

1. Maren, T. H., Carbonic anhydrase chemistry, physiology and inhibition . Physiol. Rev. 47, 595 (1967).
2. Lucci, M. S ., Tinker, J. P., Weiner, I . M., and Du Bose, T. O., Jr., Function of proximal tubule carbonic anhydrase defined by selective inhibition . Am. J. Physiol., F443 (1983).
3. Maren, T. H., Relation between structure and biological activity o f sulfonamides. Ann. Rev. Pharmacol . Toxicol . 16, 309 (1976).
4. Clapp, J. W ., and Roblin, R. O., Jr., Heterocyclic sulfonamides and methods of preparation thereof. U. S . Patent No. 2, 554, 816, issued May 29 (1951).
5. Hopkins, G. A., Drug Treatment of Glaucoma. Am. J . of Optometry & Physiological Optics. 62, 132 (1985).
6. Milichap, J. G., Acetazolamide in Treatment of Epilepsy. Lancet. July 18, ii, 8551, 163 (1987).
7. Odlind, B., Site and Mechanism of the Action of Diuretics. Acta Pharmacol . Toxicol . 54, 5 (1984).
8. Berson, F. G., Epstein, 0. L., Grant, W . M., Hutchinson, B. T., and Dobbs, P. C., Acetazolamide Dosage Forms in Treatment of Glaucoma. Arch. Opthalmol . 98, 1051 (1980).
9. Cox, S . N ., Hay, E., and Bird, A. C., Treatment of Chronic Macular Edema with Acetazolamide. Arch of Opthalmol. 106, 1190 (1988).
10. Huttenlocher, P. R., Treatment of Hydrocephalus with Acetazolamide. J . Pediatr. 66, 1023 (1965).
11. Donat, J. F., Acetazolamide Improvement in Hydrocephalus. Arch. Neurol . 37, 376 (1980).
12. Schain, R. J ., Carbonic Anhydrase Inhibitorsin Chronic Infantile Hydrocephalus. Am. J. Dis. Child. 37, 621 (1969).
13. Miner, M. E., Acetazolamide Treatment o f Progressive Hydrocephalus Secondary t o Intravenricular Hemorrhage in Preterm Infant . Child's Nerv. Syst. 2, 105 (1986).
14. Griggs, R. C., Engel, W. K., and Resnick, J. S., Acetazolamide Treatment o f Hypokalemic Periodic Paralysis: Prevention of Attacks and Improvement of Persistent Weakness. Ann. Intern. Med. 73, 39 (1970).
15. Resnick, J . S ., Engel, W. K., Griggs, R. C., and Stam, A. C., Acetazolamide Prophylaxisin Hypokalemic Periodic Paralysis. New Engl. J. Med. 278, 582 (1968).
16. Greene, M. K., Kerr, A. M., McIntosh, I. B ., and Prescott, R. J ., Acetazolamide in Prevention of Acute Mountain Sickness: a Double Blind Crossover Study. Br. Med. J. 283, 811 (1981).
17. Larson, E. B., Roach, R. C., Schone, R. B., and Hornbein, T. F., Acute Mountain Sickness and Acetazolamide: Clinical Efficacy and Effect on Ventilation. J . Am. Med. Assoc. 248, 328 (1982).
18. Birmingham Medical Research Expeditionary Society Mountain Sickness Study Group, Acetazolamide in Control of Acute Mountain Sickness. Lancet. 1, 180 (1981).
19. Wright, A. D., and Fletcher, R. F., Acute Mountain Sickness. Postgrad. Med. J. 63, 163 (1987).
20. Kelley, W. N., Richardson, A. P., Morton, M. F., and Rector, F . C. Jr ., Acetazolamide in Phenobarbital Intoxication. Arch. Intern. Med. 117, 64 (1966).
21. Freed, S . Z., The Alternating Use o f an Alkalizing Salt and Acetazolamide in the Management of Cystine and Uric Acid Stones. J. Urol. 113, 96 (1975).
22. Dickinson, G. E., Meyers, M. L., and Goldbach, M., Acetazolamide in the Treatment of Ventilatory Failure Complicating Acute Metabolic Alkalosis. Anesth. Analg. 60, 608 (1981).
23. Weiner, I. M., and Mudge, G. H., in "Pharmacological Basis of Therapeutics" (Gilman, A. G., Rall, T. W., and Murad, F., eds.), p. 879. Macmillan Publishing Company (1985).
24. Reynolds, J . E. F., in "Martindales: The Extra Pharmacopoeia", 28th ed., p. 541. The Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London (1982).
25. Anonymous, in "United States Pharmacopoeia Drug Information", Vol. 1A, 11th ed., p. 792. United States Pharmacopeial Convention, Inc., Rockville, MD.
26. Parasrampuria, J ., Development of an Oral Liquid Dosage Form of Acetazolamide. Ph. D. Thesis, Univ. Houston, Houston, Texas (1989).
27. Reynolds, J . E. F., in "Martindale: The Extra Pharmacopoeia", 29th ed., p. 975. The Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London (1989).
28. Parasrampuria, J ., and Gupta, V. D., Development of an Oral Liquid Dosage Form o f Acetazolamide. J . Pharm. Sci. 79, 835 (1991).
29. Ibrahim, S . A., and Shawky, S ., Solubility of Acetazolamide and Chlorothal idone in Mixed Aqueous Solvent Systems. Pharm. Ind. 46, 412 (1984).
30. Yalkowsky, S . H., and Roseman, T. J., Solubilization of Drugs by Cosolvents, in "Techniques of Solubilization o f Drugs'' (Yalkowsky, S . H ., ed.), p. 91. Marcel Dekker, Inc., New York (1981).
31. Umeda, T., OhnSshi, N ., Yokoyama, T., Kuroda, T., Kita, Y., Kuroda, K., Tatsumi, E., and Matsuda, Y., Physico-chemical Properties and Isothermal Transition of Acetazolamide Polymorphs. Chem. Pharm. Bull. 33, 3422 (1985). (1991).
32. Turczan, J . W ., Nuclear Magnetic Resonance Analysis of Pharmaceuticals. Part XI : Determination of Acetazolamide and its Sodium Salt in Various Dosage Forms. Analytica Chimica Acta. 68, 395 (1974).
33. Abdine, H., Elsayed, M. A., and Elsayed, Y. M., pH-Induced Difference: Spectrophotometric Assay of Acetazolamide, Hydrochlorthiazide, and Furosemide. J . Assoc. Off . Anal. Chem. 61, 695 (1978).
34. Anonymous, United States Pharmacopoeia XXII, National Formulary XVII, p. 21. United States Pharmacopeial Convention, Rockville, MD (1990).
35. Hayden, A. L., Sammul, 0. R., Selzer, G. B., and Carol, J ., Infrared, Ultraviolet, and Visible Absorption Spectra o f Some USP and NF Reference Standards and Their Derivatives. J. Assoc. Off . Anal. Chem. 45, 797 (1962).
36. Wallace, S . M., Shah, V. P., and Riegelman, S . GLC Analysis o f Acetazolamide in Blood, Plasma, and Saliva Following Oral Administration to Normal Subjects. J . Pharm. Sci. 66, 527 (1977).
37. Gupta, V. D., and Parasrampuria, J ., Quantitation of Acetazolamide in Pharmaceutical Dosage Forms Using HPLC. Pharm. Res. 3, S125 (1986).
38. Parasrampuria, J., and Gupta, V. D., Quantitation of Acetazolamide in Pharmaceutical Dosage Forms Using HPLC, Drug. Develop. Indus. Pharm. 13, 147 (1987).
39. Hwang, P. T. R., Lang, J . R., Wood, G. C., and Meyer, M. C., HPLC Determination of Acetazolamide in Human Plasma. J. Liq . Chromatography. 8, 1465 (1985).
40. Chapron, D. J ., and White, L. B., Determination of Acetazolamide in Biological Fluids by Reverse-Phase HPLC. J . Pharm. Sci. 73, 985 (1984).
41. Hartley, R., Lucock, M., Becker, M., Smith, I. J ., and Forsythe, W . I., Solid-Phase Extraction of Acetazolamide From Biological Fluids and Subsequent Analysis by HPLC. J. Chromatography. 377, 295 (1986).
42. Hossie, R. D., Mousseau, N., Sved, S ., and Brien, R., Quantitation of Acetazolamide by HPLC. J . Pharm. Sci. 69, 348 (1980).
43. Chambers, D. M., White, M. H., and Kostenbauder, H. B., Efficient Extraction and Reverse-Phase HPLC-UV Quantitation of Acetazolamide in Serum. J. Chromatography. 225, 231 (1981).
44. Gal, J ., Ellis, P. P., and Rendi, M., Determination of Acetazolamide in Biological Fluids by HPLC. Current Eye Res. 1, 361 (1981).
45. Fogg, A. G., and Ghawji, A. B., Reductive Amperometric Determination of Nitrofurantoin and Acetazolamide at a Sessile Mercury Drop Electrode Using Flow Injection Analysis. Analyst. 113, 727 (1988).
46. Parasrampuria, J ., and Gupta, V. D., Degradation Kinetics of Acetazolamide in Aqueous Systems. J . Pharm. Sci. 76, S291 (1987).
47. Parasrampuria, J., and Gupta, V. O., Preformulation Studies of Acetazolamide: Effect of pH, Two Buffer Species, Ionic Strength, and Temperature on its Stability. J. Pharm. Sci. 78, 857 (1989).
48. Parasrampuria, J ., Gupta, V. D., and Stewart, K. R., Chemical Stability of Acetazolamide Sodium in 5% Dextrose and 0.9% Sodium Chloride Injections. Am. J . Hosp. Pharm. 44, 358 (1987).
49. Parasrampuria, J., and Gupta, V. O., Effect of Temperature on the Stability of Acetazolamide in Aqueous Systems. Pharm. Res. 5, S523 (1988).
50. Parasrampuria, J ., and Gupta, V. D., Development of Liquid Oral Dosage Forms of Acetazolamide. Pharm. Res. 6, 5104 (1989).
51. Alexander, K . S ., Haribhakti, R. P., and Parker, G. A., Stability of Acetazolamide in Suspension Compounded From Tablets. Am. J . Hosp. Pharm. 48, 1241 (1991).
52. Ellis, P. P., Price, P. K., Kelmenson, R., and Rendi, M. A ., Effectiveness of Generic Acetazolamide. Arch. Opthalmol . 100, 1920 (1982).
53. Straughn, A. B., Gollamudi, R., and Meyer, M. C., Relative Bioavailability of Acetazolamide Tablets. Biopharm. Drug Dispos. 3, 75 (1982).
54. Yakatan, G. J ., Frome, E. L., Leonard, R. G., Shah, A. C., and Doluisio, J . T., Bioavailabllity of Acetazol amide Tablets. J. Pharm. Sci . 67, 252 (1978).
55. Kelly, R., Bioavailability of Sustained Release Acetazolamide. J . Pharm. Pharmacol . 38, 863 (1986).
56. Diamox (Acetazol amide) Package Insert, Lederle Laboratories, Inc., American Cyanamid Company, New York.
57. Kunka, R. L., and Mattocks, A. L., Relationship of Pharmacokinetics to Pharmacological Response for Acetazolamide. J . Pharm. Sci. 68, 347 (1979).
58. Kunka, R. L., and Mattocks, A. L., Nonlinear Model for Acetazolamide. J . Pharm. Sci. 68, 342 (1979).
59. Sweeny, K. R., Chapron, D. J., and Kramer, P. A., Effect of Salicylate on Serum Protein Binding and Red Blood Cell Uptake of Acetazolamide invitro . J . Pharm. Sci. 77, 751 (1988).
60. Chapron, O. J ., Sweeny, K. R., Feig, P.. U., and Kramer, P. A., Influence o f Advanced Aye on the Disposition of Acetazolamide. Br J. Clin. 19, 363 (1985).
61. White, G. J ., and White, M. K., Breast-feeding and Drugs in Human Milk . Vet. Human Toxicol. 22, 1 (1980).
62. Schoenwald, R. O., Garabedian, J. N., and Yakatan, G. J ., Decreased Bioaval ability of Sustained Rea ease Acetazolamide Dosage Forms. Drug Oevel op. Indus . Pharm. 4, 599 (1978).